Uncategorized

Sensorion Announces it Has Met Primary Endpoint for SENS-401 Phase 2a Clinical Study for Residual Hearing Preservation

Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, announces it has met the primary endpoint for its Proof of Concept Phase 2a clinical trial of SENS-401 for residual hearing preservation following cochlear implantation.

Sensorion Announces it Has Met Primary Endpoint for SENS-401 Phase 2a Clinical Study for Residual Hearing Preservation Read More »

Ascletis Announces Poster Presentation of Phase II Study Final Results of FASN Inhibitor ASC40 for Treatment of Acne at 2024 AAD Annual Meeting

Ascletis Pharma Inc. announces the poster presentation of Phase II study final results of ASC40, a first-in-class fatty acid synthase inhibitor for treatment of acne, at the 2024 American Academy of Dermatology Annual Meeting in San Diego, the United States.

Ascletis Announces Poster Presentation of Phase II Study Final Results of FASN Inhibitor ASC40 for Treatment of Acne at 2024 AAD Annual Meeting Read More »

Scroll to Top